Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Symbicort in Chronic Obstructive Pulmonary Disease (SYMBOL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00611520
First received: January 29, 2008
Last updated: January 27, 2011
Last verified: January 2011

January 29, 2008
January 27, 2011
September 2005
December 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00611520 on ClinicalTrials.gov Archive Site
to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population
Same as current
Not Provided
Not Provided
 
Symbicort in Chronic Obstructive Pulmonary Disease
Symbicort in Chronic Obstructive Pulmonary Disease

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients

Chronic Obstructive Pulmonary Disease
Not Provided
1
Patients with COPD treated with budesonide/formoterol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64730
Not Provided
December 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with COPD treated with budesonide/formoterol

Exclusion Criteria:

  • limitations; possible risks; warnings; contraindications mentioned in the SPC.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00611520
1312005009
No
Dr Kai Richter, AstraZeneca Germany
AstraZeneca
Not Provided
Study Chair: Kai Richter, MD Medical Department AstraZeneca Germany
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP